Biocon targets Canadian market with generic weight-loss drugs
Biocon is planning to launch affordable versions of the popular weight-loss drugs Ozempic and Wegovy in Canada by 2026, right after the patents expire.
The company is also eyeing markets like India, Latin America, and Asia-Pacific, where demand for these GLP-1 therapies is rising.
Biocon's plans for India and China
In India, Biocon will start phase-3 trials soon and aims for approval by late 2026—promising prices about 20% lower than branded Wegovy.
While they've dropped plans for China due to tough competition, Biocon believes its experience making insulin gives it an edge elsewhere.
Semaglutide's patent details
Semaglutide—the key ingredient in Ozempic and Wegovy—helps manage blood sugar and weight.
Its patent expires in many places by 2026 (but not in the US, Europe, or Japan until at least 2032), opening doors for more affordable generics like Biocon's as global competition heats up.